Rituximab

Despite an ever-growing array of therapeutic options, patients with antineutrophil cytoplasmic antibody-associated vasculitis often fail to achieve remission, according to a speaker at the ACR State-of-the-Art Clinical Symposium.

Rituximab modulated retinal atrophy in relapsing-remitting MS, with attenuating effects that may be more significant after 12 months of treatment, according to results of an observational study published in Neurology.

Despite strong biomarkers and an improved understanding of the many systems involved in IgG4 disease, no curative therapy exists, according to a speaker at the virtual American College of Rheumatology State-of-the-Art Clinical Symposium.

B-cell depletion with rituximab was safe and may be a potentially effective treatment for patients with systemic sclerosis-associated pulmonary arterial hypertension, researchers reported.

The addition of copanlisib to rituximab increased response rates and significantly extended PFS among patients with relapsed indolent non-Hodgkin lymphoma, according to study results.

Researchers in Spain found that patients with inflammatory rheumatic disease had a greater risk for developing severe COVID-19 pneumonia than the general population.

Rituximab was associated with more severe COVID-19 in patients with inflammatory rheumatic and musculoskeletal diseases, according to data published in The Lancet Rheumatology.

Patients with inflammatory rheumatic disease, but especially those with autoimmune conditions, as well as those treated with rituximab, may be at greater risk for severe COVID-19 pneumonia than the general population, according to data.

Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic autoantibody vasculitis, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

The FDA approved rituximab-arrx for multiple indications.